1174 - Pathology test to determine if a patient has been infected with CCR5 tropic HIV-1 for access to maraviroc

Page last updated: 13 July 2016

Application Detail



Description of Medical Service

A proposal was received seeking genotypic HIV tropism testing to be funded through two avenues: (1) through the creation of a new MBS item number to allow HIV tropism testing as part of the current genotype-assisted antiretroviral resistance testing suite of tests; and (2) through the creation of a new MBS item number for HIV tropism testing alone.

HIV tropism testing is a co-dependent technology to determine eligibility for access to maraviroc.

Description of Medical Condition

HIV is a viral infection that causes immunosuppression. If untreated this leads to a number of different opportunistic infections and diseases that are called Acquired Immune Deficiency Syndrome (AIDS). AIDS diseases are often life-threatening and prior to the introduction of effective antiretroviral therapies, patients with AIDS had a prognosis of around two years. The treatment of HIV-1 is complex, with the choice to treat and choice of treatment highly individualised. Treatment decisions depend on virologic efficacy, drug-drug interaction potential, resistance testing results, and co-morbid conditions.

Reason for Application


Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation

Final Decision Analytic Protocol (DAP) (PDF 137 KB)
Final Decision Analytic Protocol (DAP) (Word 390 KB)

Assessment Report

The Submission has been withheld at the request of the Applicant

Public Summary Document

Public Summary Document (PDF 737 KB)
Public Summary Document (Word 349 KB)

Meetings for this Application


14 - 15 September 2011
1 - 2 December 2011


11 - 12 October 2012


29 - 30 November 2012